HealthSource review

HealthSource publishes a price for everything it sells: sermorelin at $295, NAD⁺ injection from $279, NAD⁺ nasal spray at $179 and glutathione at $180. It claims service in all 50 states, including Alaska and Hawaii; the subscription covers medication, supplies and a telehealth visit with unlimited provider messaging, and the homepage displays a LegitScript seal. The public pages do not name the practitioner or pharmacy assigned to an order. Everything is charged every four weeks, not monthly — thirteen cycles a year — which makes the annual cost higher than the headline figures imply.

HealthSource is a telehealth weight-management and wellness storefront listing compounded semaglutide and tirzepatide alongside sermorelin, NAD⁺ injection, NAD⁺ nasal spray and glutathione. It describes an online intake, licensed-provider review and pharmacy shipping in about three to five business days after the clinical step. The seller describes a US 503A partner pharmacy without naming the facility assigned to a selected prescription and claims service in all 50 states, including Alaska and Hawaii.

A WooCommerce storefront over a telehealth visit, with each program bundling the medication, the supplies and the clinician visit into one recurring charge and adding unlimited messaging with the prescribing doctor through its patient portal. Unlimited messaging is a real inclusion rather than a slogan when you are titrating an injectable, and the product page advertises an auto-refund if a required monthly reassessment is missed. That is a seller-stated condition whose procedure is not explained; the general refund policy is narrower. It does not publicly identify the practitioner assigned to a selected order or a medical director. It displays a LegitScript seal on its homepage. The 503A partner pharmacy is disclosed as a category but never named. The public product pages do not establish baseline lab requirements or cost for a growth-hormone-axis peptide; confirm both for the selected plan. The refund terms are strict: processed charges are not refunded, and prescription orders become nonrefundable after provider completion or transmission or pharmacy processing. Cancellation must reach the service at least 48 hours before renewal.

Published for every product, which is the case for listing it, with one structural caveat that matters more than it looks. Sermorelin is $295 every four weeks, a single price with no dose tiers shown. NAD⁺ injection is from $279 every four weeks, with 1,000 mg and 2,000 mg options, and the NAD⁺ nasal spray is $179 on the same cycle. Glutathione injection is $180 every four weeks. On the weight-loss side, compounded semaglutide is from $199, injectable tirzepatide from $299 and oral tirzepatide from $399, all every four weeks. A four-week cycle produces thirteen charges in a year rather than twelve, so multiply accordingly before comparing these against a provider quoting a calendar month. The "from" framing on the NAD⁺ injection and GLP-1 programs is the second caveat: the 2,000 mg NAD⁺ price is not shown here, so ask for the selected strength and total before enrolling. Terms require cancellation at least 48 hours before renewal and do not refund a charge already processed.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. HealthSource describes its medications as dispensed through a partner 503A pharmacy but does not name it, and compounded sterile products are not reviewed by the FDA for purity and potency the way approved drugs are. The compounded status of the oral tirzepatide tablet is not explicitly labeled on the site either, though the 503A model is consistent with it — that is an inference worth confirming rather than assuming. On the evidence, sermorelin, NAD⁺ and glutathione sit on different footings. Sermorelin acts on the growth-hormone axis, a real and well-described mechanism whose long-term human outcome data stays thin, with no controlled trial behind the anti-aging claims the line is marketed under. Injected and intranasal NAD⁺ have no controlled human outcome trials; the single human intravenous study was a pharmacokinetic pilot showing infused NAD⁺ clears from plasma quickly, and the studied forms are the oral precursors NR and NMN, which raise blood NAD⁺ rather than demonstrate a clinical outcome. Injectable glutathione has essentially no controlled human outcome evidence. Individual results vary.